GlassScriptPhysician profile
Catherine A Steinkamp
NPI 1073399614
$3,056.33
in general payments reported to CMS, 2019-2025
25 companies · $2,383 in 2025
The $2,383 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $674 · 2025: $2,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,056.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,190.88 | 2024-2025 | |
| Janssen Biotech, INC. | $515.90 | 2024-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $282.91 | 2024-2025 | Otezla, Evenity, Repatha |
| Ucb, INC. | $202.26 | 2024-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $130.46 | 2024-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $118.32 | 2024-2025 | |
| Daiichi Sankyo INC. | $106.44 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $70.33 | 2025 | |
| Tandem Diabetes Care, INC. | $62.02 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Almatica Pharma LLC | $46.91 | 2025 | Teriparatide |
| Novo Nordisk INC | $36.97 | 2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $32.72 | 2025 | Capvaxive |
| Exact Sciences Corporation | $25.78 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $25.19 | 2025 | Actemra |
| Glaxosmithkline, LLC. | $22.89 | 2025 | Benlysta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals LLC | $22.70 | 2025 | Trudhesa |
| Radius Health, INC. | $20.90 | 2024 | Tymlos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.79 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $20.46 | 2024 | Nexletol |
| Scilex Pharmaceuticals INC. | $19.58 | 2025 | |
| Baxter Healthcare | $18.72 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Neurelis, INC. | $16.48 | 2025 | Valtoco |
| Aurinia Pharma U.S., INC. | $15.63 | 2024 | Lupkynis |
| Lilly USA, LLC | $15.55 | 2025 | Amyvid, Kisunla |
| Actelion Pharmaceuticals US, INC. | $15.54 | 2024 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Steinkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.